Be the first to review this item
Betoftan eye drops - is a local ophthalmic drug that belongs to the group of antiglaucomatous drugs; blocks beta-adrenoreceptors, reducing the production of intraocular fluid, thereby reducing both increased and normal intraocular pressure.
Betoftan eye drops - Antiglaucoma preparation. Betaxolol is a selective beta 1-blocker with no intrinsic sympathomimetic activity. Does not have a membrane-stabilizing (local anesthetic) action.
With topical application, betaxolol reduces both increased and normal intraocular pressure, due to decreased production of intraocular fluid. The onset of an antihypertensive effect is usually observed 30 minutes after the use of the drug, and the maximum decrease in the ophthalmotonus occurs approximately after 2 hours. After a single instillation, the effect on the ophthalmotonus persists for 12 hours.
Betaxolol, in comparison with other beta-blockers, does not cause a decrease in blood flow in the optic nerve, miosis, spasm of accommodation, hemeralopia (in contrast to myotics).
Betaxolol is highly lipophilic, as a result of which it penetrates well through the cornea into the anterior chamber of the eye, Cmax in the anterior chamber is determined 20 min after instillation. With topical application, systemic absorption is low, the concentration in the plasma is below the threshold (2 ng / ml) of detection.
Distribution and deduction
Binding to plasma proteins - 50%. T1 / 2 - 14-22 hours. It is excreted by the kidneys (15% unchanged). The permeability through the BBB and the placental barrier is low, the secretion of breast milk is negligible.
With caution appoint a drug for diabetes, thyrotoxicosis, concurrent administration of oral beta-blockers, Raynaud's syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis, AV-blockade of I degree, heart failure.
Application in childhood
Contraindicated in children and adolescents under 18 years.
Betoftan contains preservative benzalkonium chloride, which can be adsorbed by soft contact lenses and have a damaging effect on the eye tissue. Therefore, patients wearing soft contact lenses should take them off before applying drops and install, back no earlier than 20 minutes after instillation.
To prevent contamination of the pipette, do not touch the eye when instilled.
Beta-adrenoblockers should be used with caution in patients with a tendency to hypoglycemia, because these drugs can mask the symptoms of acute hypoglycemia.
Beta-blockers can mask some symptoms of hyperthyroidism (for example, tachycardia). Patients with suspected thyrotoxicosis should not abstain from beta-blockers, this can cause an increase in symptoms.
Beta-adrenoblockers can cause symptoms similar to those of myasthenia gravis (eg, diplopia, ptosis, general weakness).
Prior to the planned operation, beta-blockers should be gradually (not simultaneously) canceled 48 hours before the general anesthesia, tk. during general anesthesia, they can reduce the sensitivity of the myocardium to the sympathetic stimulation necessary for the work of the heart.
Care should be taken when assigning beta-blockers to patients with a greatly reduced function of the respiratory system. Despite the fact that clinical studies have shown no effect of betaxolol on the function of external respiration, one should not exclude the possibility of hypersensitivity to the drug.
Patients taking beta-blockers may have a history of atopy or anaphylactic reactions. In the case of repeated reactions, such patients may not be sensitive to the usual doses of epinephrine needed to stop anaphylaxis.
When instillation, the drug can enter the systemic circulation. Thus, the same side effects can be observed, as with IV, and parenteral administration of beta-blockers.
Betoftanum has minimal effect on blood pressure and heart rate. However, care should be taken when prescribing it to patients with grade I AV blockade or heart failure. Treatment should be stopped when the first signs of decompensation of the cardiovascular system appear.
Impact on the ability to drive vehicles and manage mechanisms
Patients who temporarily lose visual clarity after instillation of the drug are not recommended to engage in activities that require increased attention and reaction before recovery.
Bury 1-2 drops in the conjunctival sac 2 times / day. In some patients, intraocular pressure stabilization occurs within a few weeks, therefore it is recommended to monitor intraocular pressure during the first month of treatment.
If the required level of intraocular pressure is not achieved with monotherapy with Betoftan, additional therapy should be prescribed.
Important notice- the outer box design may vary before prior notice!
Someone from the Italy - just purchased the goods:
Kristagen 60 capsules